Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia
Stopped The study was terminated as the asset was sold to another company who decided not to pursue this indication with this drug.
Conditions
- Telangiectasia, Hereditary Hemorrhagic
Interventions
- DRUG: Pazopanib
- DRUG: Placebo
Sponsor
GlaxoSmithKline